Table of Contents Author Guidelines Submit a Manuscript
Erratum

An erratum for this article has been published. To view the erratum, please click here.

Disease Markers
Volume 2014, Article ID 671283, 3 pages
http://dx.doi.org/10.1155/2014/671283
Research Article

Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanomas

1Department of Clinical and Diagnostic Medicine and Public Health, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy
2Department of Dermatology, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy
3Department of Plastic and Reconstructive Surgery, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy
4Department of Medical Oncology, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy
5Dermatology & Skin Cancer Unit, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy

Received 10 June 2013; Revised 19 November 2013; Accepted 19 November 2013; Published 23 January 2014

Academic Editor: Dinesh Kumbhare

Copyright © 2014 Ponti Giovanni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The introduction of a newly developed target therapy for metastatic melanomas poses the challenge to have a good molecular stratification of those patients who may benefit from this therapeutic option. Practically, BRAF mutation status (V600E) is commonly screened although other non-V600E mutations (i.e., K-R-M-D) could be found in some patients who respond to therapy equally to the patients harboring V600E mutations. Furthermore, other mutations, namely, N-RAS, KIT, and GNAQ, should be sequenced according to distinct melanoma specific subtypes and clinical aspects. In our report, a practical flow chart is described along with our experience in this field.